Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma

This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaodan Luo, Ao Chen, Le Qin, Robert Weinkove, Rong Zhao, Ting Ye, Sihui Chen, Jianli Tang, Jianbo Liu, Jiayu Huang, Boyun Shi, Danyun Yuan, Huo Tan, Dajiang Qin, Zhaoyang Tang, Peng Li, Runhui Zheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	relapsed/refractory Burkitt lymphoma CAR T-cell therapy autologous hematopoietic stem cell transplantation CD19/CD22 dual target immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1497736/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma

Similar Items